|
Match
|
Document |
Document Title |
|
|
US20160158150 |
Manufacture of Pharmaceutical Compositions
The present invention relates to particles and to methods of making particles. In particular, the invention relates to methods of making composite active particles comprising a pharmaceutically... |
|
|
US20160031893 |
ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME
The present invention relates generally to the field of antimicrobial compounds and to methods of making and using them. These compounds are useful for treating, preventing, and reducing the risk... |
|
|
US20150224130 |
Solid Carriers for Improved Delivery of Active Ingredients in Pharmaceutical Compositions
The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one... |
|
|
US20150210681 |
GLUCOSYLCERAMIDE SYNTHASE INHIBITORS
The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with... |
|
|
US20140193347 |
LIPID DEPOT FORMULATIONS
The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least... |
|
|
US20140072623 |
GASTRIC RETAINED GABAPENTIN DOSAGE FORM
A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form. |
|
|
US20130023525 |
GYRASE INHIBITORS AND USES THEREOF
The present invention relates to compounds which inhibit bacterial gyrase and/or Topo IV and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions... |
|
|
US20120138056 |
DRY POWDER COMPOSITION COMPRISING CO-JET MILLED PARTICLES FOR PULMONARY INHALATION
The present invention relates to particles and to methods of making particles. In particular, the invention relates to methods of making composite active particles comprising a pharmaceutically... |
|
|
US20090297619 |
NANOPARTICULATE ANTICONVULSANT AND IMMUNOSUPPRESSIVE COMPOSITIONS
Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the... |
|
|
US20090169620 |
ORALLY DISINTEGRATING TABLET COMPOSITIONS OF TEMAZEPAM
The compositions of the present invention are orally disintegrating tablet compositions comprising a therapeutically effective amount of at least one drug such as temazepam, 0.5-3% of an ODT... |
|
|
US20090162441 |
PULMONARY DELIVERY IN TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM
A method for treating a disorder of the central nervous system includes administering to the respiratory tract of a patient a drug which is delivered to the pulmonary system, for instance to the... |
|
|
US20080248123 |
Nanoparticulate anticonvulsant and immunosuppressive compositions
Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the... |
|
|
US20080069878 |
Drug Delivery Systems Comprising Solid Solutions of Weakly Basic Drugs
The present invention is directed to pharmaceutical compositions and dosage forms comprising TPR beads, wherein said TPR beads comprise a solid dispersion of at least one active pharmaceutical... |
|
|
US20070036854 |
Therapeutic applications of pro-apoptotic benzodiazepines
Benzodiazepine compounds, and methods for using those compounds are provided. Some of the benzodiazepine compounds include 1,4-benzodiazepine-2-one and 1,4-benzodiazepine-2,5-dione compounds of... |
|
|
US20060198896 |
Aerosol and injectable formulations of nanoparticulate benzodiazepine
Described are nanoparticulate formulations of a benzodiazepine, such as lorazepam, that does not require the presence of polyethylene glycol and propylene glycol as stabilizers, and methods of... |
|
|
US20050288278 |
HIV replication inhibiting pyrimidines
This invention concerns the use of compounds of formula the N-oxides, the pharmaceutically acceptable addition salts, quaternary amines and the stereochemically isomeric forms thereof, wherein... |
|
|
US20050158249 |
Aerodynamically light particles for pulmonary drug delivery
Improved aerodynamically light particles for drug delivery to the pulmonary system, and methods for their synthesis and administration are provided. In a preferred embodiment, the aerodynamically... |
|
|
US20170151259 |
METHOD FOR THE TREATMENT OF DRAVET SYNDROME
A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its... |
|
|
US20170151257 |
METHOD FOR THE TREATMENT OF DRAVET SYNDROME
A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its... |
|
|
US20170056344 |
METHODS OF TREATING LENNOX-GASTAUT SYNDROME USING FENFLURAMINE
A method of treating and/or preventing symptoms of Lennox-Gastaut Syndrome (LGS) also known as Lennox Syndrome in a patient such as a patient previously diagnosed with Lennox Syndrome, by... |
|
|
US20160184311 |
Combination Therapy for the Treatment of Cancer
The present disclosure relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof and (2) a second agent which is... |
|
|
US20150118301 |
Immediate Release Abuse-Deterrent Granulated Dosage Forms
Described are oral dosage forms that contain abuse-deterrent features and that contain core-shell polymers that include an active pharmaceutical ingredient, with particular examples including... |
|
|
US20150118300 |
Immediate Release Abuse-Deterrent Granulated Dosage Forms
Described are oral dosage forms that contain abuse-deterrent features and that contain core-shell polymers that include an active pharmaceutical ingredient, with particular examples including... |
|
|
US20140038935 |
DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES
The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of... |
|
|
US20120087952 |
Pulmonary Delivery in Treating Disorders of the Central Nervous System
A method for treating a disorder of the central nervous system includes administering to the respiratory tract of a patient a drug which is delivered to the pulmonary system, for instance to the... |
|
|
US20120003330 |
BENZOQUINOLONE INHIBITORS OF VMAT2
The present invention relates to new benzoquinolone inhibitors of VMAT2, pharmaceutical compositions thereof, and methods of use thereof. |
|
|
US20090304801 |
AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
Described are nanoparticulate formulations of a benzodiazepine, such as lorazepam, that does not require the presence of polyethylene glycol and propylene glycol as stabilizers, and methods of... |
|
|
US20090258865 |
ADMINISTRATION OF BENZODIAZEPINE COMPOSITIONS
The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions. |
|
|
US20090111792 |
Injectable capsaicin with tricyclic antidepressant adjunctive agent
Disclosed in certain embodiments is a method for relieving pain at a site in a human or animal in need thereof, comprising administering by injection or infiltration, a dose of a capsaicinoid and... |
|
|
US20090012065 |
Therapeutic applications of pro-apoptotic benzodiazepines
Benzodiazepine compounds, and methods for using those compounds are provided. Some of the benzodiazepine compounds include 1,4-benzodiazepine-2-one and 1,4-benzodiazepine-2,5-dione compounds of... |
|
|
US20070129353 |
Alpha-helix mimetics and method relating to the treatment of cancer stem cells
The invention provides α-mimetic structures and a chemical library relating thereto. Additionally, the invention provides methods wherein a-mimetic compounds are used to treat cancer stem cells. |
|
|
US20070071687 |
INTRANASAL BENZODIAZEPINE COMPOSITIONS
A pharmaceutical composition for intranasal administration to a mammal. The pharmaceutical composition comprises an effective amount of a benzodiazepine or pharmaceutically acceptable salt... |
|
|
US20160158220 |
BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2
The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions thereof, and methods of use thereof. |
|
|
US20140242063 |
PHARMACEUTICAL COMPOSITIONS
The present invention provides for a pharmaceutical composition that includes tetrabenazine and a release-retarding agent; and a method of treating a hyperkinetic movement disorder (e.g.,... |
|
|
US20140170220 |
MULTIMODAL PARTICULATE FORMULATIONS
Multimodal particulate formulations of medicaments and methods for their use, e.g. by nasal or pulmonary administration for the treatment of various medical conditions, are provided. |
|
|
US20140128378 |
METHODS OF TREATING EPILEPTOGENESIS
The present invention is directed to the use of a class of peptide Compounds for prevention, alleviation or/and treatment of refractory Status epilepticus. |
|
|
US20140093559 |
ABUSE-PROOFED DOSAGE FORM
A solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse... |
|
|
US20130195935 |
ABUSE-PROOFED DOSAGE FORM
A solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse... |
|
|
US20120308654 |
ABUSE-PROOFED DOSAGE FORM
A solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse... |
|
|
US20120165301 |
BENZODIAZEPINE COMPOSITIONS FOR TREATING EPIDERMAL HYPERPLASIA AND RELATED DISORDERS
The present invention provides, for example, pharmaceutical compositions comprising a benzodiazepine compound and an agent selected from the group consisting of a topical steroid, a keratolytic... |
|
|
US20120135071 |
Abuse-proofed dosage form
A solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse... |
|
|
US20100055133 |
PHARMACEUTICAL COMPOSITIONS
The present invention provides for a pharmaceutical composition that includes tetrabenazine and a release-retarding agent; and a method of treating a hyperkinetic movement disorder (e.g.,... |
|
|
US20090041800 |
Methods for Treating Dependence
Provided are methods of treating patients suffering from or susceptible to at least one symptom of abuse of, dependence on, or withdrawal from at least one substance with Compound A. Also provided... |
|
|
US20060009447 |
Pharmaceutical compositions comprising midazolam in a high concentration
Compositions of midazolam, a benzodiazapine, in concentrations of 35-100 mg/ml are disclosed for the treatment of anxiety, epilepsy and epileptic seizures, invasive surgical procedures and... |
|
|
US20050025717 |
Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in... |
|
|
US20170000728 |
Controlled-Release CNS Modulating Compositions and Methods for the Treatment of Otic Disorders
Disclosed herein are compositions and methods for the treatment of otic disorders with CNS modulating agent compositions and compositions administered locally to an individual afflicted with an... |
|
|
US20150313868 |
USE OF CANNABINOIDS AND TERPENES FOR TREATMENT OF ORGANOPHOSPHATE AND CARBAMATE TOXICITY
Pharmaceutical compositions in which isolated cannabinoid receptor modulators are optionally combined with terpene blends in a pharmaceutically acceptable carrier. Methods for treating or... |
|
|
US20150174116 |
TRANSMUCOSAL DRUG DELIVERY SYSTEM
Disclosed are preparations and formulations of high thermodynamic activity lipophilic associations (LA), in which there is pairing between an ionizable pharmaceutical agent and a lipophilic... |
|
|
US20150157558 |
METHODS OF TREATMENT USING A GASTRIC RETAINED GABAPENTIN DOSAGE FORM
A method of treatment for epilepsy and other disease states is described, which comprises delivery of gabapentin in a gastric retained dosage form. |
|
|
US20150118295 |
Immediate Release Abuse-Deterrent Granulated Dosage Forms
Described are oral dosage forms that contain abuse-deterrent features and that contain core-shell polymers that include an active pharmaceutical ingredient, with particular examples including... |